← Leaderboards
Varman T Samuel
Va Connecticut Healthcare System
$1,067,637
Attributed
$1,067,637
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $240.8K · FY2005–25$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,067,637 · 2
VA$0 · 2
By mechanism
K23$627,950 · 1
R21$439,687 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pyruvate Carboxylase”
- Gerald I Shulman · Yale University$17,245,141
- Shawn C Burgess · Ut Southwestern Medical Center$6,469,451
- Richard G Kibbey · Yale University$5,644,075
- Michael John Macdonald · University Of Wisconsin Madison$5,010,712
- Ruslan Rafikov · University Of Arizona$4,511,932
- Christopher B Newgard · University Of Texas Sw Med Ctr/Dallas$4,446,684
Research focus
Pyruvate CarboxylaseFatty Acid Glycerol EstersLipidsLipid MetabolismIn VivoHepaticLiverPreventAntisense OligonucleotidesGluconeogenesisGenetic TranscriptionAffectAdipose TissueProteinsAccountingRattusObesityInsulin ResistancePathway InteractionsEnzymesNon-Insulin-Dependent Diabetes MellitusFatty LiverResearch PersonnelLipid Biosynthesis
Grant awards (17)
Exploring the mechanisms by which dietary fructose primarily impairs white adipose, not hepatic, function: insights from a novel ketohexokinase antisense oligonucleotide$0
I01 · FY2025 · VA · contact PI
Exploring the mechanisms by which dietary fructose primarily impairs white adipose, not hepatic, function: insights from a novel ketohexokinase antisense oligonucleotide$0
I01 · FY2024 · VA · contact PI
Exploring mitochondrialflux and lipid compartmentation in vivo to develop new therapies for alcoholic liver disease$198,906
R21 · FY2023 · AA · contact PI
Exploring mitochondrialflux and lipid compartmentation in vivo to develop new therapies for alcoholic liver disease$240,781
R21 · FY2022 · AA · contact PI
Cellular mechanisms for increased gluconeogenesis in type 2 diabetes mellitus: the role of lipid induced pyruvate carboxylase acetylation in increasing hepatic gluconeogenic capacity.$0
I01 · FY2020 · VA · contact PI
Cellular mechanisms for increased gluconeogenesis in type 2 diabetes mellitus: the role of lipid induced pyruvate carboxylase acetylation in increasing hepatic gluconeogenic capacity.$0
I01 · FY2019 · VA · contact PI
Cellular mechanisms for increased gluconeogenesis in type 2 diabetes mellitus: the role of lipid induced pyruvate carboxylase acetylation in increasing hepatic gluconeogenic capacity.$0
I01 · FY2018 · VA · contact PI
Cellular mechanisms for increased gluconeogenesis in type 2 diabetes mellitus: the role of lipid induced pyruvate carboxylase acetylation in increasing hepatic gluconeogenic capacity.$0
I01 · FY2017 · VA · contact PI
Cellular Mechanisms for Increased Gluconeogenesis in Type 2 Diabetes$0
I01 · FY2015 · VA · contact PI
Cellular Mechanisms for Increased Gluconeogenesis in Type 2 Diabetes$0
I01 · FY2014 · VA · contact PI
Cellular Mechanisms for Increased Gluconeogenesis in Type 2 Diabetes$0
I01 · FY2013 · VA · contact PI
Cellular Mechanisms for Increased Gluconeogenesis in Type 2 Diabetes$0
I01 · FY2012 · VA · contact PI
Mechanism of Fat Induced Hepatic Insulin Resistance$125,590
K23 · FY2006 · RR · contact PI
Mechanism of Fat Induced Hepatic Insulin Resistance$125,590
K23 · FY2005 · RR
Mechanism of Fat Induced Hepatic Insulin Resistance$125,590
K23 · FY2004 · RR
Mechanism of Fat Induced Hepatic Insulin Resistance$125,590
K23 · FY2003 · RR
Mechanism of Fat Induced Hepatic Insulin Resistance$125,590
K23 · FY2002 · RR